Market Overview

Repligen Receives First Milestone Payment from Pfizer for Development of Treatment for SMA

Share:
Related RGEN
PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter
10 Stocks That Rallied Four Days, Then Sold Off Yesterday
Repligen to Participate in –4th Annual Craig-Hallum Institutional Investor Conference (GuruFocus)
Related PFE
The Current State Of The Breast Cancer Treatment Space
Exclusive: Corium CEO Gives The Scoop On His Company's Latest Alzheimer's Data
S&P 500, Nasdaq Hit Record Highs; FANGs Bare Their Teeth (Investor's Business Daily)

Repligen Corporation (Nasdaq: RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. (NYSE: PFE) under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to treat spinal muscular atrophy (SMA). This first milestone payment was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations by Repligen. Repligen announced the Agreement in January of this year, at which time it received an upfront payment of $5 million. Repligen remains eligible to receive up to $64 million in additional success-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement.

Posted-In: News

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!